One feels you are rather confused, never implied they should withdraw but have been very critical of a2m management and there ability to inform shareholders and be on the front foot in the FDA application and new markets in general.
the critism is fully deserved.
Ann: Deferral of FDA consideration of enforcement discretion, page-126
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add A2M (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.48 |
Change
-0.110(1.67%) |
Mkt cap ! $4.684B | |||
| Open | High | Low | Value | Volume |
| $6.59 | $6.64 | $6.41 | $25.96M | 4.015M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 103592 | $6.47 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.48 | 48180 | 4 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| A2M (ASX) Chart |